KURA
PharmaKURA is a pharmaceutical company focused on Oncology, Metabolic, Gastroenterology. Key products include KOMZIFTI.
FDA Novel Drug Designations
(2025)See 1 novel approval →
KURA's Key Drugs
KURA's core commercial portfolio centers on KOMZIFTI, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
KURA's Recent FDA Approvals
KURA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
KURA's Therapeutic Areas
KURA's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
KURA's Top Competitors
KURA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Takeda, and ASTELLAS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
KURA Pipeline Snapshot
KURA has 13 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 4 Phase 2 and 8 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • KOMZIFTI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/1 completed
- • Speed: 46 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-11-13
- Latest
- 2025-11-13
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges